Cytarabine clinical trials
Also written Ara-C, Cytosar-U, DepoCyt and CHX-3311.
Its developmentBy 23 companies, company by company32 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.Includes 19 studies of Liposomal Cytarabine.
Related medicines add 1 study
Counted the way a researcher would: Cytarabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Cytarabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cytarabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jun 1969 · CYTARABINE · NDA 016793 (FDA, Drugs@FDA)
- European Union
- 11 Jul 2001 · DepoCyte · EMEA/H/C/000317 (EMA; as Liposomal Cytarabine; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
493 studies that test it; most in 2016 (28); 2 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1992 | 1 |
| 1993 | 3 |
| 1994 | 4 |
| 1995 | 6 |
| 1996 | 6 |
| 1997 | 4 |
| 1998 | 9 |
| 1999 | 13 |
| 2000 | 18 |
| 2001 | 16 |
| 2002 | 14 |
| 2003 | 22 |
| 2004 | 19 |
| 2005 | 17 |
| 2006 | 15 |
| 2007 | 24 |
| 2008 | 15 |
| 2009 | 18 |
| 2010 | 23 |
| 2011 | 14 |
| 2012 | 19 |
| 2013 | 17 |
| 2014 | 13 |
| 2015 | 14 |
| 2016 | 28 |
| 2017 | 14 |
| 2018 | 27 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 13 |
| 2023 | 13 |
| 2024 | 20 |
| 2025 | 16 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 465
M.D. Anderson Cancer Center (46) · National Cancer Institute (NCI) (37) · Children's Oncology Group (21) · St. Jude Children's Research Hospital (17) · Fred Hutchinson Cancer Center (16) · Institute of Hematology & Blood Diseases Hospital, China (13) · Memorial Sloan Kettering Cancer Center (11) · University of Washington (10)
Often tested with
Tested in the same studies.
Etoposide (102) · Cyclophosphamide (88) · Methotrexate (82) · Daunorubicin (75) · Vincristine (63) · Dexamethasone (61) · Idarubicin (59) · Mitoxantrone (48)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 10 phase 3 studies under way
Cytarabine is the comparator. A study of two new drugs counts under both.
- 2CPX-351 · University of Birmingham, University of Ulm · next primary completion Jun 2027
- 2Azacitidine · Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University · next primary completion Dec 2026
- 2Venetoclax · Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University · next primary completion Dec 2026
- 1Odronextamab · Regeneron Pharmaceuticals · next primary completion May 2028
- 1Fludarabine · University of Birmingham
- 1Busulfan · University of Birmingham
- 1Thiotepa · University of Birmingham
- 1Galinpepimut-s · Sellas Life Sciences Group
Reaching primary completion within a year · 24, 6 in phase 3
Studies that test Cytarabine, phase 3 first.
- Dec 2026Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsPhase 3 · The Affiliated People's Hospital of Ningbo University
- Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)Phase 3 · Children's Cancer Group, China
- Jan 2027Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)Phase 3 · Baylor College of Medicine
- May 2027Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.Phase 3 · King Edward Medical University
- Sep 2027A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPhase 3 · National Cancer Institute (NCI)
- Sep 2027Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaPhase 3 · Chinese PLA General Hospital
- Nov 2026Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaNot applicable · Noguchi Memorial Institute for Medical Research
- Dec 2026A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaPhase 2 · ECOG-ACRIN Cancer Research Group
- Dec 2026Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaPhase 1/2 · University of Southern California
- Dec 2026Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses Cytarabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 497
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 4St. Jude Children's Research HospitalNCT06289673Written as CytarabineHow we know
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Cytarabine (Ara-C)How we know
- Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03263572Written as CytarabineHow we know
- Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity SyndromeRecruitingPhase 2OHSU Knight Cancer InstituteNCT06895473Written as CytarabineHow we know
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as CytarabineHow we know
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingPhase 1/2University of WashingtonNCT04797767Written as CytarabineHow we know
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03125642Written as AraCHow we know
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as CytarabineHow we know
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as CytarabineHow we know
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as CytarabineHow we know
- Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSRecruitingPhase 1Stelexis BioSciencesNCT06533761Written as Eganelisib in combination with cytarabineHow we know
- Low Dose Induction for Pediatric Acute Myeloid Leukemia PatientsRecruitingNot applicableAzza Shibl SayedNCT07867600Written as Low dose Ara C/ anthracycline combined with GCSFHow we know
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Cytarabine (Ara-C)How we know
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07862517Written as CytarabineHow we know
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as CytarabineHow we know
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03586609Written as CytarabineHow we know
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07763210Written as CytarabineHow we know
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT05554419Written as CytarabineHow we know
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingPhase 2Mayo ClinicNCT03418038Written as CytarabineHow we know
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingPhase 2OHSU Knight Cancer InstituteNCT06504459Written as CytarabineHow we know
See all 497 studies that test Cytarabine →
Given beside what is tested · 484 — Cytarabine is usual care or a partner of the new treatment
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as CytarabineHow we know
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsRecruitingPhase 2Ruijin HospitalNCT07301138Written as CytarabineHow we know
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaRecruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as CytarabineHow we know
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as CytarabineHow we know
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as CytarabineHow we know
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as CytarabineHow we know
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Cytarabine (intrathecal)How we know
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT03589729Written as CytarabineHow we know
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyRecruitingPhase 2Uma BorateNCT06930352Written as CytarabineHow we know
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as CytarabineHow we know
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)RecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT07223814Written as CytarabineHow we know
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as CytarabineHow we know
- Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1City of Hope Medical CenterNCT07914166Written as CytarabineHow we know
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as CytarabineHow we know
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03214562Written as CytarabineHow we know
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as CytarabineHow we know
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07132684Written as CytarabineHow we know
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingPhase 2New York Medical CollegeNCT02393157Written as Liposomal ARA-CHow we know
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as CytarabineHow we know
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as CytarabineHow we know
Showing 20 of 484.
As the comparator · 40 — what is tested is compared with Cytarabine
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06529250Written as Daunorubicin+CytarabineHow we know
- Venetoclax Combined With Azacitidine for Consolidation Therapy in AMLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07425782Written as Ara-C GroupHow we know
- Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 MutationsNot yet recruitingPhase 2Shen yangNCT07664839Written as Cytarabine plus DaunorubicinHow we know
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+daunorubicin+cytarabineHow we know
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407140Written as Cytarabine + Daunorubicin (or Idarubicin) + GilteritinibHow we know
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07486479Written as CytarabineHow we know
- Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingPhase 2Guangdong Provincial People's HospitalNCT06451861Written as cytarabineHow we know
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as CytarabineHow we know
- AML Patients Bearing FLT3 Mutations Based on Peripheral Blast ClearanceRecruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04174612Written as CytarabineHow we know
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT06230224Written as CytarabineHow we know
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04817241Written as CytarabineHow we know
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedPhase 3Astellas Pharma IncNCT03182244Written as CytarabineHow we know
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as CytarabineHow we know
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as CYTARABINEHow we know
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedPhase 3Technische Universität DresdenNCT02688140Written as CytarabineHow we know
- The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)CompletedPhase 2Hospices Civils de LyonNCT00932412Written as HDAcHow we know
- A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingPhase 2/3University of BirminghamNCT04217278Written as CytarabineHow we know
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as CytarabineHow we know
- Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05361057Written as Venetoclax, daunorubicin, cytarabineHow we know
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as CytarabineHow we know
Showing 20 of 40.
Codes
What other systems call Cytarabine · ClinicalTrials.gg INT007290
- MeSH (NLM) D003561CytarabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 04079A1RDZCYTARABINEConfirmed FDA, NLM, Wikidata
- RxNorm 3041Confirmed FDA, Wikidata
- Wikidata Q180983cytarabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C408CytarabineOne source FDA
- DrugBank DB00987One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003561 | Cytarabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 04079A1RDZ | CYTARABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3041 | — | Confirmed FDA, Wikidata |
| Wikidata | Q180983 | cytarabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C408 | Cytarabine | One source FDA |
| DrugBank | DB00987 | — | One source Wikidata |
Also registered as cytarabine hydrochloride (UNII 33K3DB6591).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.